Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Biopharmaceutics & Drug Disposition|June 23, 2009
Metabolites in safety testing: metabolite identification strategies in discovery and developmentAngus N R NeddermanBioanalysis|November 19, 2010
Looking back through the MIST: a perspective of evolving strategies and key focus areas for metabolite safety analysisAngus N R Nedderman, Pat WrightJournal of Pharmaceutical and Biomedical Analysis|May 7, 2004
The use of 96-well Scintiplates to facilitate definitive metabolism studies for drug candidatesAngus N R Nedderman, Mark E Savage, Katharine L White, et al.Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 31, 2011
From definition to implementation: a cross-industry perspective of past, current and future MIST strategiesAngus N R Nedderman, Gordon J Dear, Stephanie North, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 15, 2005
Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIVDon K Walker, Samantha Abel, Pierre Comby, et al.British Journal of Clinical Pharmacology|March 26, 2008
Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjectsSamantha Abel, Deborah Russell, Lyndsey A Whitlock, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 4, 2010
Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteersManoli Vourvahis, Michelle Gleave, Angus N R Nedderman, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 2018
A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the "Metabolites in Safety Testing" Regulatory GuidanceSimone Schadt, Bojan Bister, Swapan K Chowdhury, et al.Pageof 1